Whoop Eyes IPO and Glucose Monitoring Integration Within Two Years

Whoop CEO Will Ahmed has confirmed the company is actively considering an IPO within the next two years, while simultaneously pushing into medical-grade territory with plans to integrate third-party continuous glucose monitoring devices. That combination of financial ambition and product expansion puts Whoop in direct competition with brands that have historically owned the clinical wearable space.

Glucose monitoring is a significant move. CGM devices like the Dexterity Stelo or Abbott Libre already appeal to endurance athletes tracking fuel metabolism, but they operate as standalone tools. If Whoop can pull real-time glucose data into its recovery and strain ecosystem, that changes how athletes calibrate nutrition around training blocks in a way no current subscription wearable does at scale.

Whoop already differentiates itself from Garmin and Coros by charging a subscription fee (starting around $30/month) with no upfront hardware cost, betting on data depth over GPS features. An IPO would pressure the company to grow that subscriber base fast, which raises a real question: does going public accelerate product development or force Whoop to play it safe to protect quarterly numbers?

For serious athletes, the glucose angle is the one worth watching. Polar and Garmin have flirted with blood glucose partnerships but delivered nothing concrete yet. If Whoop ships a working CGM integration before anyone else, that is a legitimate edge for triathletes, ultra runners, and cyclists who spend real money figuring out their carbohydrate needs during long efforts.

Not a done deal on either front. But the direction is clear. Whoop is betting its future on health data nobody else is packaging for everyday athletes.